Search

Displaying results 7031 - 7040 of 10000 in total
  1. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  2. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.

  3. Drug

    Ancriviroc

    go.drugbank.com/drugs/DB19773
    Experimental

    The usage of the INN stem '-viroc' in the name indicates that Ancriviroc is a CCR5 (Chemokine CC motif receptor 5) receptor antagonist. Ancriviroc has a monoisotopic molecular weight of 556.2 Da.

  4. Drug

    Diclofenac etalhyaluronate

    go.drugbank.com/drugs/DB20937
    Experimental

    Diclofenac etalhyaluronate has a monoisotopic molecular weight of 1475.39 Da. … The usage of the INN stem '-ac' in the name indicates that Diclofenac etalhyaluronate is a anti-inflammatory agent, ibufenac derivative.

  5. Drug

    Xemilofiban

    go.drugbank.com/drugs/DB21058
    Experimental

    Xemilofiban has a monoisotopic molecular weight of 358.16 Da. … The usage of the INN stem '-fiban' in the name indicates that Xemilofiban is a fibrinogen receptor antagonist (glycoprotein IIb/IIIa receptor antagonist).

  6. Drug

    Imdatifan

    go.drugbank.com/drugs/DB21643
    Experimental

    The usage of the INN stem '-tifan' in the name indicates that Imdatifan is a hypoxia inducible factor (HIF)-2alpha (HIF-2a) inhibitor. Imdatifan has a monoisotopic molecular weight of 385.05 Da.

  7. Drug

    Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15740
    Investigational

    Currently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application. … In humans, OM-MSCs are derived from the olfactory mucosa which is collected in vivo through rhinoscopy techniques and nasal forceps.

  8. Drug

    Alphameprodine

    go.drugbank.com/drugs/DB01499
    ExperimentalIllicit

    Alphameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. … It exerts physiological effects characteristic of opioids, such as analgesia, euphoria and sedation, as well as itching, nausea, and respiratory depression.

  9. Drug

    Renzapride

    go.drugbank.com/drugs/DB04917
    Investigational

    It has been suggested that renzapride is effective in the treatment of irritable bowel syndrome with alternating stool pattern. It is being developed by Alizyme of the UK. … Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C).

  10. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant has a monoisotopic molecular weight of 478.13 Da. … Eliapixant is under investigation in clinical trial NCT04614246 (Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive